Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC

•Addition of immunotherapy for treatment of metastatic non-small lung cancer does not increase cardiovascular toxicity.•Treatment with immunotherapy and chemotherapy had 19 % lower hazards for cardiovascular toxicity as compared with chemotherapy alone.•This study did not find any significant increase in pericarditis, myocarditis or cardiomyopathy associated with immunotherapy use.•Immunotherapy might have cardio-protective effects with unclear mechanism and needs further exploration.